China Biologic Products (CBPO) Earning Somewhat Positive News Coverage, Study Finds
News headlines about China Biologic Products (NASDAQ:CBPO) have trended somewhat positive on Thursday, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. China Biologic Products earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.5500912235497 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Brokerages Expect China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 EPS (americanbankingnews.com)
- China Biologic Announces Corporate Update – PR Newswire (press release) (prnewswire.com)
- Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Improved Earnings Growth In Recent Times? (finance.yahoo.com)
- China Biologic to Attend the 36th Annual J.P. Morgan Healthcare Conference (finance.yahoo.com)
Several equities analysts have recently weighed in on CBPO shares. BidaskClub raised China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 20th. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $137.50.
China Biologic Products (CBPO) opened at $79.26 on Thursday. China Biologic Products has a 1-year low of $72.21 and a 1-year high of $120.46. The stock has a market capitalization of $2,730.00, a price-to-earnings ratio of 20.64, a P/E/G ratio of 1.00 and a beta of 1.79.
TRADEMARK VIOLATION WARNING: “China Biologic Products (CBPO) Earning Somewhat Positive News Coverage, Study Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/china-biologic-products-cbpo-earning-somewhat-positive-news-coverage-study-finds/1802111.html.
China Biologic Products Company Profile
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with Analyst Ratings Network's FREE daily email newsletter.